QIAGEN and Procognia Enter into a Marketing and Licensing Agreement Targeting the Field of Protein Glycoanalysis
QIAGEN N.V. announced that it has obtained an exclusive license from Procognia Limited to market and sell Procognia's proprietary "on-chip" protein glycoanalysis technology. The company believes the new products based on Procognia's technology to be an excellent enhancement of its successfully launched Qproteome protein fractionation product line, which addresses a range of different applications in life science research, including drug development and clinical research.
Procognia's "on-chip" glycoanalysis products consist of lectin chips and analytical software developed and manufactured by Procognia. These products will be combined with a selection of QIAGEN's QProteome product line to create novel, "guided fractionation" solutions which should address previously unmet needs in proteomics and systems biology. QIAGEN believes that this novel protein glycoanalysis technology addresses a previously unmet need for the preparation and understanding of proteins in the rapidly emerging field of glycomics. Financial terms were not disclosed.
"By integrating Procognia's "on-chip" glycoanalysis into our Qproteome line, we are creating novel "guided-fractionation" solutions for the exciting field of glycomics", said Peer Schatz, QIAGEN's Chief Executive Officer. "We expect this technology to significantly accelerate QIAGEN's leadership in preanalytical solutions in this rapidly growing area of proteomics."
Other news from the department business & finance
